CYP3A1(23)诱导对糖尿病大鼠克拉霉素药代动力学的影响。
Effect of CYP3A1(23) induction on clarithromycin pharmacokinetics in rats with diabetes mellitus.
作者信息
Kim Yu C, Lee Joo H, Kim So H, Lee Myung G
机构信息
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, San 56-1, Shinlim-Dong, Kwanak-Gu, Seoul 151-742, South Korea.
出版信息
Antimicrob Agents Chemother. 2005 Jun;49(6):2528-32. doi: 10.1128/AAC.49.6.2528-2532.2005.
Abstract
After intravenous and oral administration of clarithromycin at a dose of 20 mg/kg of body weight to rats with diabetes mellitus induced by alloxan (DMIA) and diabetes mellitus induced by streptozotocin (DMIS), the area under the curve values were significantly smaller than those of respective control rats. The in vitro intrinsic clearance values for the disappearance of clarithromycin were significantly faster in both rats with DMIA and rats with DMIS than in control rats. The above data suggested that metabolism of clarithromycin increased in both types of diabetic rat due to an increase in the expression and mRNA level of CYP3A1(23) in the rats.
摘要
给用四氧嘧啶诱导的糖尿病大鼠（DMIA）和用链脲佐菌素诱导的糖尿病大鼠（DMIS）静脉注射和口服20mg/kg体重的克拉霉素后，曲线下面积值显著小于各自的对照大鼠。克拉霉素消失的体外内在清除率值在DMIA大鼠和DMIS大鼠中均显著快于对照大鼠。上述数据表明，由于大鼠中CYP3A1(23)表达和mRNA水平增加，两种类型的糖尿病大鼠中克拉霉素的代谢均增加。
相似文献
1
Effect of CYP3A1(23) induction on clarithromycin pharmacokinetics in rats with diabetes mellitus.CYP3A1(23)诱导对糖尿病大鼠克拉霉素药代动力学的影响。
Antimicrob Agents Chemother. 2005 Jun;49(6):2528-32. doi: 10.1128/AAC.49.6.2528-2532.2005.
2
Changes in omeprazole pharmacokinetics in rats with diabetes induced by alloxan or streptozotocin: faster clearance of omeprazole due to induction of hepatic CYP1A2 and 3A1.用四氧嘧啶或链脲佐菌素诱导的糖尿病大鼠中奥美拉唑药代动力学的变化：由于肝CYP1A2和3A1的诱导，奥美拉唑清除加快。
J Pharm Pharm Sci. 2007;10(4):420-33. doi: 10.18433/j3wc7g.
3
Telithromycin pharmacokinetics in rat model of diabetes mellitus induced by alloxan or streptozotocin.
Pharm Res. 2008 Aug;25(8):1915-24. doi: 10.1007/s11095-008-9610-7. Epub 2008 May 14.
4
Pharmacokinetics and pharmacodynamics of intravenous torasemide in diabetic rats induced by alloxan or streptozotocin.静脉注射托拉塞米在四氧嘧啶或链脲佐菌素诱导的糖尿病大鼠中的药代动力学和药效学
Biopharm Drug Dispos. 2005 Nov;26(8):371-8. doi: 10.1002/bdd.467.
5
Pharmacokinetics of clarithromycin in rats with acute renal failure induced by uranyl nitrate.
Biopharm Drug Dispos. 2004 Sep;25(6):273-82. doi: 10.1002/bdd.409.
6
Pharmacokinetics of diclofenac in rat model of diabetes mellitus induced by alloxan or steptozotocin.双氯芬酸在四氧嘧啶或链脲佐菌素诱导的糖尿病大鼠模型中的药代动力学
Biopharm Drug Dispos. 2006 Mar;27(2):85-92. doi: 10.1002/bdd.484.
7
Pharmacokinetics of theophylline in diabetes mellitus rats: induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation.糖尿病大鼠中茶碱的药代动力学：CYP1A2和CYP2E1对1,3-二甲基尿酸形成的诱导作用
Eur J Pharm Sci. 2005 Sep;26(1):114-23. doi: 10.1016/j.ejps.2005.05.004.
8
Pharmacokinetics of oltipraz in rat models of diabetes mellitus induced by alloxan or streptozotocin.奥替普拉在四氧嘧啶或链脲佐菌素诱导的糖尿病大鼠模型中的药代动力学
Life Sci. 2006 Apr 11;78(20):2287-94. doi: 10.1016/j.lfs.2005.09.031. Epub 2005 Nov 8.
9
Pharmacokinetics of phenytoin and its metabolite, 4'-HPPH, after intravenous and oral administration of phenytoin to diabetic rats induced by alloxan or streptozotocin.给用四氧嘧啶或链脲佐菌素诱导的糖尿病大鼠静脉注射和口服苯妥英后，苯妥英及其代谢产物4'-羟基苯妥英的药代动力学。
Biopharm Drug Dispos. 2008 Jan;29(1):51-61. doi: 10.1002/bdd.591.
10
The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.肠道和肝脏细胞色素P450 3A对咪达唑仑与克拉霉素相互作用的影响。
Clin Pharmacol Ther. 1998 Aug;64(2):133-43. doi: 10.1016/S0009-9236(98)90146-1.
引用本文的文献
1
Comparison of pharmacokinetic parameters of ranolazine between diabetic and non-diabetic rats.糖尿病大鼠与非糖尿病大鼠中雷诺嗪药代动力学参数的比较。
Iran J Basic Med Sci. 2022 Jul;25(7):865-870. doi: 10.22038/IJBMS.2022.64391.14156.
2
Modulation of CYP3a expression and activity in mice models of type 1 and type 2 diabetes.1 型和 2 型糖尿病小鼠模型中 CYP3a 表达和活性的调节。
Pharmacol Res Perspect. 2014 Dec;2(6):e00082. doi: 10.1002/prp2.82. Epub 2014 Sep 1.
3
Strategies for preclinical pharmacokinetic investigation in streptozotocin-induced diabetes mellitus (DMIS) and alloxan-induced diabetes mellitus (DMIA) rat models: case studies and perspectives.链脲佐菌素诱导的糖尿病（DMIS）和四氧嘧啶诱导的糖尿病（DMIA）大鼠模型临床前药代动力学研究策略：案例分析与展望
Eur J Drug Metab Pharmacokinet. 2015 Mar;40(1):1-12. doi: 10.1007/s13318-014-0186-9. Epub 2014 Mar 6.
本文引用的文献
1
Pharmacokinetics of clarithromycin in rats with acute renal failure induced by uranyl nitrate.
Biopharm Drug Dispos. 2004 Sep;25(6):273-82. doi: 10.1002/bdd.409.
2
Pharmacokinetics, blood partition and protein binding of DA-7867, a new oxazolidinone.新型恶唑烷酮类药物DA-7867的药代动力学、血液分配及蛋白结合情况
Biopharm Drug Dispos. 2004 Apr;25(3):127-35. doi: 10.1002/bdd.394.
3
Effects of cysteine on the pharmacokinetics of intravenous clarithromycin in rats with protein-calorie malnutrition.半胱氨酸对蛋白质-热量营养不良大鼠静脉注射克拉霉素药代动力学的影响。
Life Sci. 2003 Aug 22;73(14):1783-94. doi: 10.1016/s0024-3205(03)00540-x.
4
[Changes of CYP2E1 activity in diabetic rat model].[糖尿病大鼠模型中细胞色素P450 2E1活性的变化]
Yao Xue Xue Bao. 1998 Dec;33(12):891-5.
5
Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus.对用四氧嘧啶诱导的糖尿病大鼠静脉注射和口服呋塞米后的药代动力学和药效学变化
Biopharm Drug Dispos. 1998 Sep;19(6):357-64. doi: 10.1002/(sici)1099-081x(199809)19:6<357::aid-bdd114>3.0.co;2-g.
6
Pharmacokinetics of a new carbapenem, DA-1131, after intravenous administration to rats with alloxan-induced diabetes mellitus.新型碳青霉烯类药物DA-1131对四氧嘧啶诱导的糖尿病大鼠静脉给药后的药代动力学
Biopharm Drug Dispos. 1998 Jul;19(5):303-8. doi: 10.1002/(sici)1099-081x(199807)19:5<303::aid-bdd103>3.0.co;2-5.
7
Effect of bitter melon (Momordica charantia) fruit juice on the hepatic cytochrome P450-dependent monooxygenases and glutathione S-transferases in streptozotocin-induced diabetic rats.苦瓜（苦瓜属）果汁对链脲佐菌素诱导的糖尿病大鼠肝脏细胞色素P450依赖性单加氧酶和谷胱甘肽S-转移酶的影响。
Biochem Pharmacol. 1996 Nov 22;52(10):1639-42. doi: 10.1016/s0006-2952(96)00526-6.
8
Pharmacokinetic changes of methotrexate after intravenous administration to streptozotocin-induced diabetes mellitus rats.
Res Commun Mol Pathol Pharmacol. 1996 Sep;93(3):343-52.
9
Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition.呋塞米在蛋白质 - 热量营养不良中的药代动力学和药效学
J Pharmacokinet Biopharm. 1993 Feb;21(1):1-17. doi: 10.1007/BF01061772.
10
Insulin-mimetic effects of vanadate in preventing the increase of P450IIIA and P450IA subfamily proteins in streptozotocin-diabetic rats.
Acta Diabetol. 1993;30(3):128-31. doi: 10.1007/BF00572855.
Zotero 插件